137 related articles for article (PubMed ID: 32943543)
21. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
22. Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability.
Gilbert S; Péant B; Malaquin N; Tu V; Fleury H; Leclerc-Desaulniers K; Rodier F; Mes-Masson AM; Saad F
Mol Cancer Ther; 2022 Mar; 21(3):407-418. PubMed ID: 34965959
[TBL] [Abstract][Full Text] [Related]
23. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
24. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
Tang JC; An R; Jiang YQ; Yang J
Cancer Res Treat; 2017 Jul; 49(3):778-789. PubMed ID: 27857021
[TBL] [Abstract][Full Text] [Related]
25. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance.
Edlind MP; Hsieh AC
Asian J Androl; 2014; 16(3):378-86. PubMed ID: 24759575
[TBL] [Abstract][Full Text] [Related]
26. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
[TBL] [Abstract][Full Text] [Related]
27. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
Burton DG; Giribaldi MG; Munoz A; Halvorsen K; Patel A; Jorda M; Perez-Stable C; Rai P
PLoS One; 2013; 8(6):e68003. PubMed ID: 23840802
[TBL] [Abstract][Full Text] [Related]
29. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
[TBL] [Abstract][Full Text] [Related]
30. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
[TBL] [Abstract][Full Text] [Related]
31. Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction.
Al-Wahab Z; Mert I; Tebbe C; Chhina J; Hijaz M; Morris RT; Ali-Fehmi R; Giri S; Munkarah AR; Rattan R
Oncotarget; 2015 May; 6(13):10908-23. PubMed ID: 25895126
[TBL] [Abstract][Full Text] [Related]
32. Sanggenol L Induces Apoptosis and Cell Cycle Arrest via Activation of p53 and Suppression of PI3K/Akt/mTOR Signaling in Human Prostate Cancer Cells.
Won YS; Seo KI
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075054
[TBL] [Abstract][Full Text] [Related]
33. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
Kim SM; Park JH; Kim KD; Nam D; Shim BS; Kim SH; Ahn KS; Choi SH; Ahn KS
Phytother Res; 2014 Mar; 28(3):423-31. PubMed ID: 23686889
[TBL] [Abstract][Full Text] [Related]
34. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
35. Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K/Akt pathway.
Zhu S; Jiao W; Xu Y; Hou L; Li H; Shao J; Zhang X; Wang R; Kong D
Life Sci; 2021 Dec; 286():120046. PubMed ID: 34653428
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.
Etheridge T; Damodaran S; Schultz A; Richards KA; Gawdzik J; Yang B; Cryns V; Jarrard DF
Asian J Urol; 2019 Jan; 6(1):57-64. PubMed ID: 30775249
[TBL] [Abstract][Full Text] [Related]
37. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.
Zhang D; He D; Xue Y; Wang R; Wu K; Xie H; Zeng J; Wang X; Zhau HE; Chung LW; Chang LS; Li L
Cancer Res; 2011 Mar; 71(6):2193-202. PubMed ID: 21385902
[TBL] [Abstract][Full Text] [Related]
38. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling.
Malaguarnera R; Sacco A; Morcavallo A; Squatrito S; Migliaccio A; Morrione A; Maggiolini M; Belfiore A
Endocrinology; 2014 Apr; 155(4):1207-21. PubMed ID: 24437490
[TBL] [Abstract][Full Text] [Related]
39. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Liu L; Dong X
PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
[TBL] [Abstract][Full Text] [Related]
40. CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.
Roca H; Varsos ZS; Pienta KJ
Neoplasia; 2009 Dec; 11(12):1309-17. PubMed ID: 20019839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
